New potent inhibitors of angiotensin converting enzyme.
Using an earlier model of the favoured orientation of binding functions of angiotensin converting enzyme (ACE) inhibitors, it has been possible to postulate a new, 7,6-bicyclic system, based on hexahydropyridazine, which might be expected to have high potency. Some members of this system which have been synthesised have been shown to be very active ACE inhibitors, in vitro and in vivo.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D002216:Captopril / Q000031:analogs & derivatives* / Q000494:pharmacology; D017315:Cilazapril; D004151:Dipeptides / Q000494:pharmacology; D004656:Enalapril; D006801:Humans; D008968:Molecular Conformation; D011392:Proline / Q000031:analogs & derivatives*; D011724:Pyridazines / Q000494:pharmacology*; D011817:Rabbits; D013329:Structure-Activity Relationship; D013552:Swine
D000806:Angiotensin-Converting Enzyme Inhibitors; D001643:Bridged Bicyclo Compounds; D004151:Dipeptides; D011724:Pyridazines; D017315:Cilazapril; D004656:Enalapril; C028342:compound 20; C040303:Ro 31-2201; D011392:Proline; D002216:Captopril